# Lawrence Bloch

> Lawrence Bloch is a Series B investor backing Neuroscience and Therapeutics. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Location: Cambridge, United States
- Total investments: 2
- Last investment: Sep 2010
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/lawrence-bloch/62/87a/329

Lawrence Bloch is a Series B investor in Cambridge focused on Neuroscience and Therapeutics. Lawrence Bloch, M.D., J.D. is the former President of Infinity. He joined the company as chief financial officer and chief business officer in 2012 and has played a key role in developing and executing the company’s corporate and financial strateBeforeior to joining Infinity in 2012, Dr. Bloch served as chief executive officer of NeurAxon, Inc., acompany focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc., raising $150 million in equity and $20 million in venture debt to support the commercial launch of BiDil®. From 1999 to 2004, he served as chief financial officer and vice president of business development of Applied Molecular Evolution, Inc., leading the company’s $101 million initial public offering and $420 million merger with Eli Lilly and Company.Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Women’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical, School, and an MBA from Harvard Business School.

## Contacts

5 contacts available for Lawrence Bloch: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/lawrence-e-bloch?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Neuroscience | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Debt Financing | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NeurAxon | NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada. | $14M | Debt Financing | Sep 30, 2010 | http://www.neuraxon.com/ |
| NeurAxon | NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada. | $32M | Series B | Aug 20, 2007 | http://www.neuraxon.com/ |

2 of 2 investments shown.

## Co-investors
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 2 deals together
- [H.I.G. Capital](https://shizune.co/investors/profile/hig-capital) — VC Fund, 2 deals together
- [Ventures West](https://shizune.co/investors/profile/ventures-west) — VC Fund, 2 deals together
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 1 deal together
- [CTI Life Sciences Fund](https://shizune.co/investors/profile/cti-life-sciences-fund-2) — VC Fund, 1 deal together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in Canada](https://shizune.co/investors/biotech-angel-investors-canada)
- [Biotechnology Angel Investors in Canada](https://shizune.co/investors/biotechnology-angel-investors-canada)

## FAQ

### What does Lawrence Bloch invest in?

Lawrence Bloch invests primarily in Neuroscience, Therapeutics and Biotechnology startups, most often at Series B and Debt Financing stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Lawrence Bloch?

Public channels for Lawrence Bloch include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Lawrence Bloch last invest?

The most recent investment recorded for Lawrence Bloch closed in Sep 2010. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co